ATXS
Price
$8.47
Change
+$0.16 (+1.93%)
Updated
Oct 13 closing price
Capitalization
478M
29 days until earnings call
BCYC
Price
$8.12
Change
-$0.20 (-2.40%)
Updated
Oct 13 closing price
Capitalization
562.77M
16 days until earnings call
Interact to see
Advertisement

ATXS vs BCYC

Header iconATXS vs BCYC Comparison
Open Charts ATXS vs BCYCBanner chart's image
Astria Therapeutics
Price$8.47
Change+$0.16 (+1.93%)
Volume$312.78K
Capitalization478M
Bicycle Therapeutics
Price$8.12
Change-$0.20 (-2.40%)
Volume$192.69K
Capitalization562.77M
ATXS vs BCYC Comparison Chart in %
ATXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
BCYC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ATXS vs. BCYC commentary
Oct 14, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATXS is a StrongBuy and BCYC is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 14, 2025
Stock price -- (ATXS: $8.47 vs. BCYC: $8.12)
Brand notoriety: ATXS and BCYC are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATXS: 81% vs. BCYC: 66%
Market capitalization -- ATXS: $478M vs. BCYC: $562.77M
ATXS [@Biotechnology] is valued at $478M. BCYC’s [@Biotechnology] market capitalization is $562.77M. The market cap for tickers in the [@Biotechnology] industry ranges from $104.45B to $0. The average market capitalization across the [@Biotechnology] industry is $2.02B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATXS’s FA Score shows that 0 FA rating(s) are green whileBCYC’s FA Score has 1 green FA rating(s).

  • ATXS’s FA Score: 0 green, 5 red.
  • BCYC’s FA Score: 1 green, 4 red.
According to our system of comparison, ATXS is a better buy in the long-term than BCYC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATXS’s TA Score shows that 5 TA indicator(s) are bullish while BCYC’s TA Score has 5 bullish TA indicator(s).

  • ATXS’s TA Score: 5 bullish, 4 bearish.
  • BCYC’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, BCYC is a better buy in the short-term than ATXS.

Price Growth

ATXS (@Biotechnology) experienced а +10.14% price change this week, while BCYC (@Biotechnology) price change was -1.34% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.18%. For the same industry, the average monthly price growth was +13.62%, and the average quarterly price growth was +80.86%.

Reported Earning Dates

ATXS is expected to report earnings on Nov 12, 2025.

BCYC is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Biotechnology (+1.18% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BCYC($563M) has a higher market cap than ATXS($478M). ATXS YTD gains are higher at: -5.257 vs. BCYC (-42.000). ATXS has higher annual earnings (EBITDA): -131.42M vs. BCYC (-240.81M). BCYC has more cash in the bank: 721M vs. ATXS (259M). ATXS has less debt than BCYC: ATXS (4.77M) vs BCYC (7.2M). BCYC has higher revenues than ATXS: BCYC (19.3M) vs ATXS (0).
ATXSBCYCATXS / BCYC
Capitalization478M563M85%
EBITDA-131.42M-240.81M55%
Gain YTD-5.257-42.00013%
P/E RatioN/AN/A-
Revenue019.3M-
Total Cash259M721M36%
Total Debt4.77M7.2M66%
FUNDAMENTALS RATINGS
ATXS vs BCYC: Fundamental Ratings
ATXS
BCYC
OUTLOOK RATING
1..100
1278
VALUATION
overvalued / fair valued / undervalued
1..100
50
Fair valued
18
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9897
PRICE GROWTH RATING
1..100
4051
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
9050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BCYC's Valuation (18) in the null industry is in the same range as ATXS (50) in the Biotechnology industry. This means that BCYC’s stock grew similarly to ATXS’s over the last 12 months.

BCYC's Profit vs Risk Rating (100) in the null industry is in the same range as ATXS (100) in the Biotechnology industry. This means that BCYC’s stock grew similarly to ATXS’s over the last 12 months.

BCYC's SMR Rating (97) in the null industry is in the same range as ATXS (98) in the Biotechnology industry. This means that BCYC’s stock grew similarly to ATXS’s over the last 12 months.

ATXS's Price Growth Rating (40) in the Biotechnology industry is in the same range as BCYC (51) in the null industry. This means that ATXS’s stock grew similarly to BCYC’s over the last 12 months.

ATXS's P/E Growth Rating (100) in the Biotechnology industry is in the same range as BCYC (100) in the null industry. This means that ATXS’s stock grew similarly to BCYC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATXSBCYC
RSI
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
80%
Bearish Trend 1 day ago
87%
Momentum
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 1 day ago
85%
MACD
ODDS (%)
Bullish Trend 1 day ago
82%
N/A
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
82%
Bearish Trend 1 day ago
88%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
87%
Bullish Trend 1 day ago
82%
Advances
ODDS (%)
Bullish Trend 5 days ago
81%
Bullish Trend 5 days ago
82%
Declines
ODDS (%)
Bearish Trend 19 days ago
90%
Bearish Trend 1 day ago
87%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
72%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
87%
View a ticker or compare two or three
Interact to see
Advertisement
ATXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
BCYC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
VIDMX10.48N/A
N/A
Virtus KAR Developing Markets I
EKJAX12.60N/A
N/A
Allspring Premier Large Co Gr A
FEYCX29.23N/A
N/A
Fidelity Advisor Asset Manager 85% C
RRGRX7.22N/A
N/A
DWS RREEF Global Real Estate Secc R6
ESCQX11.05N/A
N/A
Embark Small Cap Equity Retirement

ATXS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATXS has been loosely correlated with XENE. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if ATXS jumps, then XENE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATXS
1D Price
Change %
ATXS100%
+1.93%
XENE - ATXS
52%
Loosely correlated
+0.88%
CRNX - ATXS
51%
Loosely correlated
-1.11%
COGT - ATXS
51%
Loosely correlated
-0.43%
DNLI - ATXS
51%
Loosely correlated
-2.54%
NRIX - ATXS
50%
Loosely correlated
-0.41%
More

BCYC and

Correlation & Price change

A.I.dvisor indicates that over the last year, BCYC has been loosely correlated with RPTX. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if BCYC jumps, then RPTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BCYC
1D Price
Change %
BCYC100%
-2.40%
RPTX - BCYC
54%
Loosely correlated
+1.11%
RGNX - BCYC
43%
Loosely correlated
+3.85%
ATXS - BCYC
43%
Loosely correlated
+1.93%
XNCR - BCYC
43%
Loosely correlated
+7.14%
AUTL - BCYC
42%
Loosely correlated
-0.60%
More